

Creating Global Solutions

AusBiotech2010
AUSTRALIA'S BIOTECHNOLOGY CONFERENCE

**National
Conference**

19 to 22 October 2010
Melbourne Convention and Exhibition Centre
www.ausbiotech2010.com.au

**Victoria
AUSTRALIA**

BioNet™
Asia Pacific

AUSBIOTECH 2010 NATIONAL CONFERENCE SPEAKERS' PROFILE

Sue Charles
Managing Partner
College Hill Life Sciences
London, United Kingdom



Sue was formerly co-founder and CEO of Northbank Communications, a highly-regarded Life Sciences consultancy that was acquired by College Hill in October 2007. She has more than 20 years' communications experience, across financial, corporate, science and marketing communications, and is regarded as an industry leader in Life Science communications. In addition to communications experience, Sue has spent time as CEO of a biotech spin-out and has had a number of non-executive positions. She has a first class degree in Biochemistry from Oxford and an MBA from Cranfield Business School.

Sue's expertise is at the interface of innovation and wealth creation, in particular advising clients where transformational science will have a high profile impact. Notably she led the global media relations on the announcement of Dolly the cloned sheep. Her experience spans both private and publically-listed biotech companies as well as pharma and not-for-profit. She works closely with boards and senior management to craft messages and outreach programmes that will maximise value creation.

Whilst leading the College Hill's Life Sciences team on a global basis from London, Sue is also based part time in Sydney. She has worked with a number of Australian biotech companies including, for example, Biota. She currently provides part-time support to the Science Faculty at the University of Technology in its Industry Engagement.

As Managing Partner, Sue offers senior level counsel across the College Hill life sciences portfolio and maintains team leadership on a select number of clients including Index Ventures and Prosensa.

Current and past experience includes: Ablynx, Abraxis BioScience, Affymetrix, Akubio, Amersham Life Sciences, Astex Therapeutics, Axxima Pharmaceuticals, Bicycle Therapeutics, BioInvent International, BioProgress, Biota, British Council – Darwin Now, BTG, CABI International, CAT (MedImmune/AZ), Cellmark Diagnostics, Cerenis Therapeutics, Cyclacel, Diamand Light Source, DTI-BMB Initiative, DxS, Funxional Therapeutics, HUGO/HGM, Illumina, Imperial Innovations, Inpharmatica (Galápagos), International Biotech Trust, Karus Therapeutics, Living Cell Technologies, Medical Futures, Merck Serono, Merlin BioSciences, Midatech, Molecular Partners, Morphochem, Nestlé Nutrition, Novartis, Oxagen, Oxford BioMedica, Oxford

Gene Technology, Oxonica, PanGenetics, Physiomics, PowderMed (Pfizer), PPL Therapeutics (Dolly), Pronota, QIAGEN, RespiVert, Santaris Pharma, SETSquared Partnership, Sigma-Aldrich, Siogen Biotech, Smiths Detection, SmithKline Beecham, SR Pharma (now Silence Therapeutics), Sugen Europe, SV Life Sciences, Syngenta Biopharm, Trigen and Wellcome Diagnostics.